Shanghai, China, 09 October 2025 — MicroPort® Coronary, a subsidiary of MicroPort Scientific Corporation (HKEX: 00853), recently announced a major milestone: cumulative global shipments and implantations of its coronary stent systems have each surpassed 10 million units as of September 2025. This achievement highlights the company’s sustained leadership in interventional cardiology and fast-growing global footprint.
Expanding Access to Cardiovascular Innovation
MicroPort® Coronary’s stent systems are now used in over 4,000 hospitals across China and are supported by clinical programs like the “FireSwallow Plan,” which has extended access to advanced interventional therapies to more than 1,300 county-level hospitals. Since launching its first drug-eluting stents in 2004, the company has maintained a leading domestic market share and has served over 6 million patients in China, with a current market share of 43%.
On the global stage, MicroPort® Coronary products are now available in more than 90 countries and regions, with a presence in over 3,000 hospitals. The company has achieved significant breakthroughs in strategic and emerging markets across Europe, Asia, South America, and North America. From 2021 to 2024, international sales of its drug-eluting stents (DES) have grown at a compound annual growth rate of 35%, with the international DES portfolio expanding by over 300% during the same period. Overseas volumes now account for nearly 30% of total sales, with projected 400,000 units to be shipped globally in 2025.
“These milestones reflect the strength of our brand, the clinical reliability of our products, and the success of our hybrid go-to-market model combining global platforms and distributor partnerships,” said Jasmine Liang, Commercial Head of Overseas Business, MicroPort®. “We are accelerating the global rollout of next-generation innovations such as Firehawk™ Liberty, intravascular lithotripsy system, OCT imaging systems, and bioresorbable stents, and will continue to deepen our presence in key international markets.”
A Legacy of Innovation in Coronary Interventions
Since its founding in 1998, MicroPort® has continuously advanced innovation in coronary technology. Its first drug-eluting stent, Firebird™, was launched in 2004 and quickly achieved 40% market share in China. This was followed by Firebird2™, and the breakthrough Firehawk™ in 2014. In 2024, the company launched Firesorb™, its next-generation bioresorbable scaffold, further extending its innovation pipeline.
Today, the MicroPort® coronary portfolio includes five stent systems tailored to a wide range of patient needs:
Beyond stents, MicroPort® Coronary is building a full-solution ecosystem for coronary artery disease, integrating passive devices, active equipment, and advanced imaging. Its portfolio now includes a coronary rotational atherectomy system, OCT imaging devices, and intravascular lithotripsy system. A piezoelectric wire system is expected to receive regulatory approval in China this year, and other technologies, such as the coronary sinus balloon pump system, are advancing rapidly toward clinical deployment.
Strong Clinical Evidence Supporting Global Recognition
MicroPort® Coronary’s technology is backed by robust clinical data. Most recently, results from the TARGET-FIRST trial were simultaneously published in the New England Journal of Medicine and presented at the 2025 European Society of Cardiology (ESC) Congress.
This landmark study showed that in selected low-risk acute myocardial infarction (AMI) patients, treatment with the Firehawk™ Liberty allowed for the safe reduction of dual antiplatelet therapy (DAPT) from 12 months to just 1 month, without increasing ischemic risk, while reducing bleeding complications by 54%. These groundbreaking findings have drawn interest from leading cardiology societies, including the American College of Cardiology (ACC) and American Heart Association (AHA). In addition, as early as 2018, another clinical study involving Firehawk™, the TARGET AC, was published in the Lancet for its breakthrough in addressing the challenge of late-stage thrombosis.
To date, more than 17,500 patients have been enrolled in the TARGET series of Firehawk™ trials across 200+ medical centers worldwide. The recently launched Firesorb™ stent has also completed 3–5 year follow-ups across over 1,400 patients through its FUTURE series of clinical studies.
Looking Ahead: From Milestones to Global Leadership
“This milestone is more than a number; it reflects the trust of physicians, the lives of millions of patients, and our commitment to continually raise the standard of coronary care,” said Dr. Bin Yue, President of MicroPort® Coronary. “As we look ahead, MicroPort® will continue advancing innovation across our entire product portfolio, from stents and imaging systems to intelligent surgery and remote care, with the ambition to become a global leader in coronary intervention.”
Mr. Lei Jiang, Chief Marketing Officer of MicroPort® Greater China and Chairman of MicroPort® Coronary, added: “This 10-million-unit achievement marks a significant step forward, not only for MicroPort®, but for China’s MedTech industry as a whole, moving from follower to global innovator. Today, that momentum extends far beyond coronary stents - across surgical robotics, structural heart, electrophysiology, and intelligent medical systems. As a group, we remain committed to our mission: to deliver trustworthy, state-of-the-art solutions that prolong and reshape lives worldwide.”
About MicroPort®
Since 1998, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can live better and longer lives. As a global medical device company, MicroPort® provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, endovascular, neurovascular and surgical robotics. Serving over 100 countries and 20,000 hospitals, MicroPort® provides a medical solution to a patient every 5 seconds.
Disclaimer: The clinical outcomes and related data presented in this article are based on publicly available clinical research or official corporate disclosures. They do not constitute medical advice or product promotion. For any medical diagnosis or treatment questions, please consult a qualified healthcare professional